Zytiga (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

HORSHAM, PA, Feburary 8, 2018 – The Janssen Pharmaceutical Companies of Johnson&Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga (abiraterone acetate) in combination with...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news

Related Links:

Helen Macdonald and Carl Heneghan are back again talking about what's happened in the world of evidence this month. (1.05) Carl rants about bacon causing cancer (7.10) Helen talks about prostate cancer, and we hear from the author of the research paper which won Research Paper Of The Year at the BMJ awards. We also cover disease definition and...
Source: The BMJ Podcast - Category: General Medicine Authors: Source Type: podcasts
Publication date: Available online 24 May 2019Source: European UrologyAuthor(s): Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, Francesco Giganti, Massimo Valerio, Yaalini Shanmugabavan, Keiran D. Clement, Debashis Sarkar, Yiannis Philippou, David Thurtle, Jonathan Deeks, Mark Emberton, Yemisi Takwoingi, Caroline M. MooreAbstractContextMagnetic resonance imaging (MRI)-targeted prostate biopsy (MRI-TB) may be an alternative to systematic biopsy for diagnosing prostate cancer.ObjectiveThe primary aims of this systematic review and meta-analysis were to compare the detection rates of clinically significant and clinic...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 23 May 2019Source: European UrologyAuthor(s): Boris Hadaschik, Piet Ost
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 23 May 2019Source: European UrologyAuthor(s): Michael Froehner, Christian Thomas
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conclusions: The PI-RADS outperforms the standard staging method using mpMRI and may assist the decision-making process regarding the extent of resection during ERP without increasing the risk of PSM. PMID: 31118993 [PubMed]
Source: Videosurgery and Other Miniinvasive Techniques - Category: Surgery Tags: Wideochir Inne Tech Maloinwazyjne Source Type: research
To investigate the adoption of abiraterone and enzalutamide by urologists. Abiraterone and enzalutamide are oral therapies approved for the treatment of metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
Black men with nonmetastatic prostate cancer did not appear more likely to die from this disease than white men when given similar access to care and standardized treatment, an analysis found.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
ConclusionWe generated a second-generation CAR targeting either Lewis Y or GRP-78 with a truncated CD34-tag for purification. Because the differentiation and phenotype of the CAR-T product may have a critical impact on the post-infusion antitumor effect and persistence of the cells, we also investigated the phenotype of CAR-T product with different γc cytokines, i.e. IL-2, IL-7 and IL-15, to generate early differentiation stage cells with less exhaustion phenotypes. In the optimized protocol, by using the retroviral transduction system, starting from 3 × 107 PBMC, we're now able to produce approximately 109...
Source: Cytotherapy - Category: Cytology Source Type: research
In conclusion, these results suggest that the health-care system in Nordland County successfully delivers state-of-the-art oncology care to patients with mPC. PMID: 31120400 [PubMed - in process]
Source: Rural Remote Health - Category: Rural Health Authors: Tags: Int J Circumpolar Health Source Type: research
ConclusionsIn patients with at least one negative PB, mpMRI + COG-TB sequence improves 3.5 (OR = 3.49) times the diagnosis prostate vs. ClTB.ResumenIntroducciónEl objetivo es comparar el rendimiento de la secuencia resonancia magnética (RM) y biopsia transrectal «cognitiva» (BTRCog) frente a la biopsia transrectal clásica (BTRCl) en pacientes con al menos una biopsia de próstata (BP) negativa.Material y métodoAnálisis retrospectivo de 205 pacientes con al menos una BP negativa. A 144 (70,2%) pacientes se les realizó antes de la biopsia una RM ...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Drugs & Pharmacology | Food and Drug Administration (FDA) | Prednisone | Prostate Cancer